Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
Cue Biopharma announced a board transition effective May 29, 2026, with four independent directors—Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen—resigning from the board. The company simultaneously appointed Daniel Camardo, a former CEO with extensive commercial launch experience, and Viola Meehan, a former CFO with deep strategic finance expertise, to fill the vacancies.
Key figures
- New directors count
- 2
- Resigned directors count
- 4
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.